BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 23466651)

  • 1. Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
    Lu Z; Tian Y; Salwen HR; Chlenski A; Godley LA; Raj JU; Yang Q
    Anticancer Drugs; 2013 Jun; 24(5):484-93. PubMed ID: 23466651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
    Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1.
    Cho HS; Kelly JD; Hayami S; Toyokawa G; Takawa M; Yoshimatsu M; Tsunoda T; Field HI; Neal DE; Ponder BA; Nakamura Y; Hamamoto R
    Neoplasia; 2011 Aug; 13(8):676-84. PubMed ID: 21847359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IVMBIX-01294, an inhibitor of the histone methyltransferase EHMT2, disrupts histone H3 lysine 9 (H3K9) dimethylation in the cleavage-stage porcine embryo.
    Park KE; Johnson CM; Cabot RA
    Reprod Fertil Dev; 2012; 24(6):813-21. PubMed ID: 22781932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.
    Hwang S; Kim S; Kim K; Yeom J; Park S; Kim I
    BMB Rep; 2020 Nov; 53(11):576-581. PubMed ID: 32684241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
    Kim H; Choi SY; Lim J; Lindroth AM; Park YJ
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32028644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.
    Kim Y; Kim YS; Kim DE; Lee JS; Song JH; Kim HG; Cho DH; Jeong SY; Jin DH; Jang SJ; Seol HS; Suh YA; Lee SJ; Kim CS; Koh JY; Hwang JJ
    Autophagy; 2013 Dec; 9(12):2126-39. PubMed ID: 24322755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.
    Yang Q; Tian Y; Ostler KR; Chlenski A; Guerrero LJ; Salwen HR; Godley LA; Cohn SL
    BMC Cancer; 2010 Jun; 10():286. PubMed ID: 20546602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
    Chen G; Yu X; Zhang M; Zheng A; Wang Z; Zuo Y; Liang Q; Jiang D; Chen Y; Zhao L; Jiang L; Li D; Liao S
    Cytogenet Genome Res; 2019; 158(4):205-212. PubMed ID: 31434093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of BIX-01294 on H3K9me2 levels and the imprinted gene Snrpn in mouse embryonic fibroblast cells.
    Chen P; Yao JF; Huang RF; Zheng FF; Jiang XH; Chen X; Chen J; Li M; Huang HF; Jiang YP; Huang YF; Yang XY
    Biosci Rep; 2015 Aug; 35(5):. PubMed ID: 26285804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-κB.
    Park SE; Yi HJ; Suh N; Park YY; Koh JY; Jeong SY; Cho DH; Kim CS; Hwang JJ
    Oncotarget; 2016 Jun; 7(26):39796-39808. PubMed ID: 27174920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Methyltransferases G9a/
    Souza BK; Freire NH; Monteiro TS; Herlinger AL; Jaeger M; Dalmolin MGS; de Farias CB; Gregianin L; Brunetto AT; Brunetto AL; Thiele CJ; Roesler R
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma.
    Gu S; Tian Y; Chlenski A; Salwen HR; Lu Z; Raj JU; Yang Q
    Anticancer Drugs; 2012 Nov; 23(10):1054-66. PubMed ID: 22863973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
    Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
    Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
    Tao H; Li H; Su Y; Feng D; Wang X; Zhang C; Ma H; Hu Q
    Mol Cell Biochem; 2014 Sep; 394(1-2):23-30. PubMed ID: 24833465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inhibition of G9a attenuates cell proliferation via the mitochondrial apoptosis pathway in lung adenocarcinoma].
    Wan HJ; Lyu W; Yu L; Zhou ZY; Hu YJ; Hu J
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):13-17. PubMed ID: 28104027
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanism of G9a inhibitor BIX‑01294 acting on U251 glioma cells.
    Guo AS; Huang YQ; Ma XD; Lin RS
    Mol Med Rep; 2016 Nov; 14(5):4613-4621. PubMed ID: 27748874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
    Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
    Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
    Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
    Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.
    Fan HT; Shi YY; Lin Y; Yang XP
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7808-7815. PubMed ID: 31599405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.